Results 71 to 80 of about 23,499 (227)
Origin of the Allyl Group in FK506 Biosynthesis [PDF]
Journal of Biological Chemistry, 2010 FK506 (tacrolimus) is a secondary metabolite with a potent immunosuppressive activity, currently registered for use as immunosuppressant after organ transplantation. FK506 and FK520 are biogenetically related natural products that are synthesized by combined polyketide synthase/nonribosomal peptide synthetase systems.
Dusan, Goranovic +7 more
openaire +2 more sources
Risk Factors and Management of Gingival Enlargement: A Systematic Review and Meta‐Analysis
Journal of Clinical Periodontology, EarlyView.ABSTRACT Objective To identify risk factors/indicators of gingival enlargement (GE) and to summarise evidence for its management. Methods A systematic review was undertaken following PRISMA guidelines and divided into PECOTS and PICOTS questions, related to risk factors/indicators and treatment studies, respectively.
Luigi Nibali +5 more
wiley +1 more source
Tacrolimus (FK506)-Associated Renal Pathology [PDF]
Advances in Anatomic Pathology, 1997 A variety of renal lesions have been described in patients undergoing episodes of tacrolimus nephrotoxicity. Although helpful to the pathologist seeking morphologic clues to substantiate drug toxicity, none of these lesions is specific to the extent that it has not been reported in other conditions.
Randhawa, Parmjeet S +2 more
openaire +2 more sources
Overview of FK506 in transplantation. [PDF]
, 1990 FK506 is a potent immunosuppressive agent which is undergoing clinical testing in liver, kidney, heart, and bone marrow transplantation. It has been shown to effectively prevent and reverse ongoing rejection in these models.
Tzakis, A +19 more
core
The role of acquired host immunity in periodontal diseases
Periodontology 2000, EarlyView.Abstract The aim of this narrative review is to relate the contribution of European researchers to the complex topic of the host immune system in periodontal disease, focusing on acquired immunity. Other chapters in this volume will address the genetics and autoantibody responses and other forms of immunity to periodontal disease.
Denis F. Kinane +2 more
wiley +1 more source
Evaluation of Synthetic FK506 Analogues as Ligands for the FK506-Binding Proteins 51 and 52
, 2016 The FK506-binding proteins (FKBP) 51 and 52 are cochaperones that modulate the signal transduction of steroid hormone receptors. Both proteins have been implicated in prostate cancer.
Ranganath Gopalakrishnan (849484) +6 more
core +1 more source
In Vitro and In Vivo Assessment of FK506 Analogs as Novel Antifungal Drug Candidates
, 2021 FK506 (tacrolimus) is an FDA-approved immunosuppressant indicated for the prevention of allograft rejections in patients undergoing organ transplants.
윤여준, 송명종
core +1 more source
Study on the Effect of Immunosuppressive Agent FK506 on Growth and Migration of Lung Cancer Cell
Chinese Journal of Lung Cancer, 2017 Background and objective FK506, also named tacrolimus, a new macrolide immunosuppressive agent, has been shown to possess anti-proliferation activities in some cancer cells.
Yongwen LI +7 more
doaj +1 more source
Balkan Medical Journal, 2018 Background: Free radical damage is known to occur during liver regeneration. The Ginkgo biloba extract EGb761 has antioxidant properties due to its ability to scavenge free radicals.
Nahide Ekici Günay +2 more
doaj +1 more source
Heart failure in two male patients with late‐onset Fabry mutation (IVS4 + 919G > A)
ESC Heart Failure, Volume 12, Issue 2, Page 1508-1513, April 2025.
Xufei Yang +3 more
wiley +1 more source